Program Announcement for the Defense Health Agency

Pancreatic Cancer Research Program Translational Research Partnership Award

Funding Opportunity Number: HT942526PCARPTRPA

Pre-Application Due: July 7, 2026

Application Due: October 7, 2026

This program announcement must be read in conjunction with the General Application Instructions, version CD26_01.

Content

Before You Begin

- **Active SAM.gov, eBRAP.org and Grants.gov registrations are required for application submission.** User registration for each of these websites can take several weeks or longer. Each applicant must ensure their registrations are active and up to date prior to application preparation.
- **Read this funding opportunity announcement in the order it is written before beginning to prepare application materials.** It is the responsibility of the applicant to determine whether the proposed research meets the intent of this funding opportunity and that all parties meet eligibility requirements.
- **To support application preparation, additional resources are available** including an application process FAQ, a Guide for Intragovernmental & Intramural Applicants and a CDMRP Video Series detailing the application process.

Who to Contact for Support

eBRAP Help Desk

301-682-5507
help@eBRAP.org

Questions regarding funding opportunity submission requirements, as well as technical assistance related to pre-application or intramural application submission.

Grants.gov Support Center

800-518-4726
International: 1-606-545-5035
support@grants.gov

Questions regarding Grants.gov registration and Workspace.

This document uses internal links; you can go back to where you were by pressing the Alt + left arrow keys (Windows) or command + left arrow keys (Macintosh) on your keyboard.

Click** ⓘ **to be taken to additional guidance and instructions within the General Application Instructions (GAI).

1. Basic Information About the Funding Opportunity

Summary: The fiscal year 2026 (FY26) Pancreatic Cancer Research Program (PCARP) Translational Research Partnership Award supports partnerships between clinicians, population scientists, applied scientists and/or basic scientists that will accelerate the movement of promising ideas in pancreatic cancer toward clinical applications. The partnership must include at least one member with expertise in pancreatic cancer research or pancreatic cancer patient care. All applications must address at least one of the FY26 PCARP Focus Areas.

- This award mechanism requires preliminary data to support feasibility of the research hypothesis(es) and research approaches. However, these data do not necessarily need to originate from studies of pancreatic cancer. Applications can support retrospective tissue analysis, correlative studies and pilot clinical trials; however, this mechanism does not allow large-scale clinical trials.
- **The Translational Research Partnership Award requires two Principal Investigators (PIs)** referred to as the Initiating PI and the Partnering PI. Only the Initiating PI will submit a pre-application, but both PIs will need to submit at the full application stage. The partnering PI's application is an abbreviated package specific to their distinct portion of the research project. Be advised, all associated applications for a research project may be withdrawn if the initiating or partnering application is rejected or administratively withdrawn.

Funding Details: The Congressionally Directed Medical Research Programs (CDMRP) expects to allot roughly $6.60 million (M) to fund approximately six Translational Research Partnership Award applications with combined total cost caps of $1.10M. The maximum period of performance is 3 years. It is anticipated that awards made from this FY26 funding opportunity will be funded with FY26 funds, which will expire for use on September 30, 2032. Awards supported with FY26 funds will be made no later than September 30, 2027.

Submission and Review Dates and Times

- **Pre-Application (Preproposal) Submission Deadline:** 5:00 p.m. Eastern Time (ET), July 7, 2026
- **Invitation to Submit an Application:** August 13, 2026
- **Application Submission Deadline:** 11:59 p.m. ET, October 7, 2026
- **End of Application Verification Period:** 5:00 p.m. ET, October 13, 2026
- **Peer Review:** December 2026
- **Programmatic Review:** January 2027

Announcement Type: Initial

Funding Opportunity Number: HT942526PCARPTRPA

Assistance Listing Number: 12.420

2. Eligibility Information

2.1. Eligible Applicants

2.1.1. Organization

Extramural and intramural U.S. Department of War (DOW) organizations are eligible to apply, ***including foreign and domestic organizations, for-profit and nonprofit organizations, and public or private entities***.

2.1.2. Principal Investigator

Independent investigators at any career level affiliated with an eligible organization are eligible to be named Initiating PI or Partnering PI on the application, regardless of ethnicity, nationality or citizenship status.

At least one of the PIs (Initiating PI or Partnering PI) must have expertise in pancreatic cancer research or pancreatic cancer patient care.

An investigator may be named on only one FY26 PCARP Translational Research Partnership Award application as Initiating PI or Partnering PI.

Postdoctoral fellows, clinical fellows and equivalent are not eligible to be named Initiating PI or Partnering PI on the application.

2.2. Cost Sharing

Cost sharing is not an eligibility requirement.

2.3. Other

Awards are made to eligible ***organizations***, not to individuals. Refer to the GAI for additional recipient qualification requirements.

3. Program Description

The Defense Health Agency Contracting Activity (DHACA) is soliciting applications to this funding opportunity using delegated authority provided by United States Code, Title 10, Section 4001 (10 USC 4001). The CDMRP is the program office managing this FY26 funding opportunity as part of the PCARP. The CDMRP is located within the Defense Health Agency Research and Development (DHA R&D), which is a part of the Department of Defense, DOD, herein referred to using the secondary title Department of War, DOW. Congress initiated the PCARP in 2020 to provide support for pancreatic cancer research of high potential impact and exceptional scientific merit. Appropriations for the PCARP from FY20 through FY24 totaled $66M. The FY26 appropriation is $20M.

The vision of the PCARP is to reduce the burden of pancreatic cancer among Service Members, Veterans, their Families, and the American public. The mission of the PCARP is to promote rigorous, innovative, high-impact pancreatic cancer research that leads to prevention, earlier diagnosis, new therapeutic tools, and improved outcomes.

3.1. Award History

The PCARP Translational Research Partnership Award mechanism was first offered in FY20. Since then, 88 Translational Research Partnership Award applications were received, and 16 were recommended for funding.

3.2. Intent of the Translational Research Partnership Award

The PCARP Translational Research Partnership Award supports partnerships between clinicians, population scientists, applied scientists and/or basic scientists that will accelerate the movement of promising ideas in pancreatic cancer toward clinical applications. This award enables two independent investigators to collaborate on translational research, addressing a central problem or question in pancreatic cancer more effectively than they could through separate efforts. Both investigators must demonstrate equal intellectual input in the design of the research project. At least one partner must have expertise in pancreatic cancer research or patient care. ***The PCARP encourages projects that involve convergence science partnerships*** and inclusion of experts from outside the pancreatic cancer field. A project where one partner merely supplies tissue samples or patient access will not meet the intent of this mechanism. Applications can support retrospective tissue analysis, correlative studies and pilot clinical trials; however, this mechanism does not allow large-scale clinical trials.

3.2.1. Focus Areas for Translational Research Partnership Award

- Early detection research.
- Identification and characterization of risk.
- Supportive care, quality of life and survivorship research.
- Understanding metabolic disruptions and their systemic effects, including diabetes and cachexia.
- Understanding tumor development from precursors to metastasis.
- Biomarkers to predict therapeutic response and guide management strategies.
- New therapeutic targets and approaches.

3.2.2. Key Elements for the Translational Research Partnership Award

Partnership: This mechanism requires two PIs. One PI will be identified as the Initiating PI and will be responsible for the majority of the administrative tasks associated with application submission. The other PI will be identified as a Partnering PI. Both PIs should contribute significantly to the development and execution of the proposed research project. Each partner should contribute unique skills and contributions to ensure the project's success. The proposed study must include clearly stated plans for interactions between the PIs and the institutions involved. The plans must include communication, coordination of research progress and results, and data transfer. Additionally, multi-institutional applications must provide an intellectual property plan to resolve potential intellectual and material property issues and remove institutional barriers that might interfere with achieving high levels of cooperation to ensure the successful completion of this award. If recommended for funding, each PI will be named on separate awards to the recipient organization(s). Each award will be subject to separate reporting, regulatory, and administrative requirements. For individual submission requirements for the Initiating and Partnering PI, refer to Section 5.3, Submission Instructions.

Translation: The application should provide evidence for the reciprocal transfer of information between basic and clinical science, or vice versa, in developing and implementing the research plan. Translational research may include correlative studies and/or development or use of annotated biorepositories. The application should demonstrate how the study will leverage clinical information to address knowledge gaps in resulting outcomes, validate key research findings, expand upon potentially transformative results and/or investigate novel findings. The ultimate goal of translational research is to move a concept or observation forward into clinical application that is relevant to active-duty Service Members, Veterans, their Families, and the American public. However, investigators should not view translational research as a one-way continuum from bench to bedside. The research plan should involve a reciprocal flow of ideas and information with an intellectual synergistic partnership.

Impact: The proposed research must have the potential to make a significant impact on pancreatic cancer research and/or patient care and accelerate the movement of promising ideas in prevention, diagnosis, detection, prognosis, treatment and/or survivorship into clinical applications.

Feasibility: The application should demonstrate that the investigators have access to the necessary specimens, data and/or intervention, as applicable.

Preliminary Data: This award mechanism ***requires preliminary data*** to support the feasibility of the research hypothesis(es) and research approaches. However, these data do not necessarily need to originate from studies of pancreatic cancer. Preliminary data may include published and/or unpublished results from the laboratory of the PIs or proposed collaborators that are relevant to pancreatic cancer and the proposed research project. Observations derived from a laboratory discovery, population-based studies or a clinician's firsthand knowledge of patients and anecdotal data may drive the research idea(s).

3.2.3. Other Important Considerations for the Translational Research Partnership Award

This mechanism allows clinical research studies and small, pilot clinical trials.

In accordance with the National Defense Authorization Act for Fiscal Year 2026, Section 732, CDMRP does not support the conduct of painful research (U.S. Department of Agriculture pain category D or E) involving domestic cats or dogs, except for studies relating to military or service animals.

All projects should adhere to a core set of standards for rigorous study design and reporting to maximize the reproducibility and translational potential of clinical and preclinical research, such as those described in the STROBE, CONSORT, SPIRIT and ARRIVE 2.0 guidelines.

Applications from investigators within the DOW and applications involving multidisciplinary collaborations among academia, industry, the DOW, the U.S. Department of Veterans Affairs (VA) and other federal government agencies are highly encouraged. These relationships can leverage knowledge, infrastructure and access to unique clinical populations that the collaborators bring to the research effort, ultimately advancing research that is of significance to Service Members, Veterans, their Families, and the American Public. If the proposed research relies on access to unique resources or databases, the application must describe the access at the time of submission and include a plan for maintaining access as needed throughout the proposed research.

A congressionally mandated Metastatic Cancer Task Force was formed with the purpose of identifying ways to help accelerate clinical and translational research aimed at extending the lives of advanced state and recurrent patients. As a member of the Metastatic Cancer Task Force, CDMRP encourages applicants to review the recommendations and submit research ideas to address these recommendations provided they are within the limitations of this funding opportunity and fit within the FY26 PCARP priorities.

3.3. Funding Instrument

The funding instrument for awards made under the program announcement will be grants (31 USC 6304).

3.4. Funding Details

Period of Performance: The maximum period of performance is **3** years.

Cost Cap: The combined total costs in the applications of the Initiating PI and the Partnering PI budgeted for the entire period of performance should not exceed **$1.10M**. If indirect cost rates have been negotiated, indirect costs are to be budgeted in accordance with the organization's negotiated rate. Collaborating organizations should budget associated indirect costs in accordance with each organization's negotiated rate.

A separate award will be made to each PI's organization.

The PIs are expected to be partners in the research, and direct cost funding should be divided accordingly unless otherwise warranted and clearly justified.

All direct and indirect costs of any subaward or contract must be included in the direct costs of the primary award.

The applicant may request the entire maximum funding amount for a project that may have a period of performance less than the maximum **3** years.

The appropriateness of the budget for the proposed research will be assessed during peer review.

Direct Cost Restrictions: For this award mechanism, direct costs:

May be requested for (not all-inclusive):

- Support for multidisciplinary collaborations, including travel.

- Costs for up to two investigators (i.e., one for each PI's budget) to travel to one scientific/technical meeting per year. The intent of travel to scientific/technical meetings should be to present project information or disseminate project results from the FY26 PCARP Translational Research Partnership Award.
- If applicable, research subject compensation and reimbursement for study-related out-of-pocket costs (e.g., travel, lodging, parking, costs associated with caregiving, and resources/equipment to enable participation).

4. Application Contents and Format

4.1. Application Overview

Application submission is a two-step process requiring both a ***pre-application*** submitted via the Electronic Biomedical Research Application Portal (eBRAP) and a ***full application*** submitted through eBRAP or Grants.gov. Depending on the submission portal, certain aspects of the application will differ.

Intramural DOW organizations submitting a full application should follow instructions for submission through eBRAP.

Extramural organizations submitting a full application must follow instructions for submission through Grants.gov.

4.2. Pre-Application Components

The Initiating PI must submit the following pre-application components.

Upload documents as individual PDF files unless otherwise noted. Files must comply with the formatting guidelines listed in the GAI.

- **Preproposal Narrative (two-page limit):** The Preproposal Narrative page limit applies to text and non-text elements (e.g., figures, tables, graphs, photographs, diagrams, chemical structures, drawings) used to describe the project. Inclusion of URLs that provide additional information to expand the Preproposal Narrative and could confer an unfair competitive advantage is prohibited and may result in administrative withdrawal of the pre-application.

  The Preproposal Narrative should include the following:

  - **Research Idea:** State the hypothesis the research will test or the objective it will reach. State which FY26 PCARP Focus Area(s) the research will address. Detail the scientific rationale that forms the basis of the proposed project and briefly describe relevant preliminary data. Concisely state the specific aims and provide a brief overview of the study design. If the proposed research includes a clinical trial, briefly state the clinical intervention, subject population(s), and phase of the clinical trial.
  - **Partnership:** Describe how the collaborative efforts of the PIs will result in a level of productivity greater than that achievable by each PI working independently. Describe how the combined efforts center on a unified objective and how the PIs will work together to achieve that objective from different perspectives. Briefly describe the PIs' histories of collaborative study with each other or with other investigators, including the PIs' abilities to function synergistically in a project among equals.
  - **Impact:** Describe the potential impact of this study on the outcomes of individuals with pancreatic cancer, their families/caregivers and/or the understanding of pancreatic cancer.
- **Pre-Application Supporting Documentation:** The items to be included as supporting documentation for the pre-application ***must be uploaded as individual files*** and are limited to the following:
  - **References Cited (one-page limit):** List the references cited (including URLs if available) in the Preproposal Narrative using a standard reference format that includes

the full citation (i.e., author[s], year published, reference title, and reference source, including volume, chapter, page numbers and publisher, as appropriate).

- **List of Abbreviations, Acronyms and Symbols:** Provide a list of abbreviations, acronyms and symbols used in the Preproposal Narrative.
- **Key Personnel Biographical Sketches: *All biographical sketches should be uploaded as a single combined file.*** Biographical sketches should be used to demonstrate background and expertise through education, positions, publications, and previous work accomplished.

4.3. Full Application Components

Applicants must receive an invitation to submit a full application. Uninvited full application submissions will be rejected.

The CDMRP requires separate full application package submissions for the Initiating PI and the Partnering PI, even if the PIs are located within the same organization. The application submission process for the Partnering PI uses an abbreviated full application package.

4.3.1. Full Application Components for the Initiating PI

Each application submission must include the completed full application package for this program announcement. See Appendix 1 for a checklist of the full application components.

(a) SF424 Research & Related Application for Federal Assistance Form *(Grants.gov submissions only)*:

IMPORTANT: *When completing the SF424 R&R, enter the* ***eBRAP log number*** *assigned during pre-application submission into* ***Block 4a – Federal Identifier****.*

(b) Attachments:

Each attachment of the full application components must be uploaded as an individual file in the format specified and in accordance with the formatting guidelines in the GAI.

- **Attachment 1: Project Narrative (15-page limit): Upload as "ProjectNarrative.pdf".**

  Describe the proposed project in detail using the outline below.

  Outline for projects without a clinical trial:

  - **Background:** Present the ideas and scientific rationale behind the proposed research; include relevant literature citations, preliminary data and/or preclinical data that led to the development of the proposed study. Preliminary data should come from the laboratory of the PIs or member(s) of the collaborating team.
  - **Hypothesis(es)/Objective(s):** State the hypothesis(es) the study will test and/or overall objective(s) it will reach.
  - **Specific Aims:** Concisely explain the project's specific aims. If this application is part of a larger study, present only tasks that this award would fund.
  - **Research Strategy and Feasibility:**
    - Describe the experimental design, methods, and analyses, including appropriate controls, in sufficient detail for an assessment of overall project feasibility. Provide a well-developed, well-integrated, and detailed research plan that

supports the translational feasibility and promise of the approach. Include specific examples of synergistic elements incorporated into the research design. Address potential problem areas and present alternative methods and approaches. Consult appropriate guidelines to ensure relevant aspects of rigorous and reproducible research are adequately planned for and, ultimately, reported.

- If the research includes animal studies, briefly describe the relevance of the proposed animal model and provide full details in the required Animal Research Plan (Attachment 8).
- If applicable, describe and justify the appropriateness of the human subject population relative to the study objectives. If the research will involve human subjects or human biological samples, include a detailed plan for the recruitment of subjects or the acquisition of samples. Where relevant, describe the availability of and access to tissue, data, or human subjects. If applicable, provide appropriate letters of support as part of the application's Supporting Documentation (Attachment 2).
- If applicable, describe the strategy for the inclusion of women and minorities appropriate to the objectives of the study, including a description of the composition of the proposed study population in terms of sex, racial and ethnic group, and an accompanying rationale for the selection of subjects. Studies utilizing human biospecimens or datasets that cannot be linked to a specific individual, ethnicity, or race (typically classified as exempt from Institutional Review Board [IRB] review) are exempt from this requirement. Anticipated enrollment table(s) with the proposed enrollment distributed on the basis of sex, race and ethnicity should be provided as part of the application's Supporting Documentation (Attachment 2).

– **Data Collection and Statistical Analysis Plan:** Describe the proposed methods for data collection and analysis in a manner that is consistent with the study objectives. Detail a statistical plan for the resulting outcomes. Include a power analysis to demonstrate the appropriateness of the sample size relative to the objectives of the study. If applicable, explain any anticipated subgroup analyses and justify the appropriateness of the sample size for the subpopulation. If applicable, describe how data will be appropriately reported and documented to support a regulatory filing with the Food and Drug Administration (FDA) or an equivalent international regulatory agency.

– **Research Team:** Describe how the combined backgrounds and pancreatic cancer-related experience of the research team will enable successful conduct of the project.

– **Project Coordination and Communication:** Describe plans for communication, decision-making, allocation of resources, coordination of research progress and results, and sharing of data among both PIs and institutions participating in the project.

Outline for projects with a clinical trial:

Note: The Project Narrative is NOT the formal clinical trial protocol. Instead, the application must describe all elements of the proposed pilot clinical trial necessary for peer review as indicated below.

- **Background:** Present the ideas and scientific rationale behind the proposed research; include relevant literature citations, preliminary data and/or preclinical data that led to the development of the proposed study. Preliminary data should come from the laboratory of the PIs or member(s) of the collaborating team.
  - Clearly support the choice of study variables and explain the basis for the study question(s) and/or study hypothesis(es). Establish the relevance of the study and explain the applicability of the proposed findings.
  - If another funding source supported initiation of the proposed clinical trial, explain the trial's history and background and declare the source of prior funding. Identify the portions of the study that this award would support.
- **Hypothesis(es)/Objective(s):** State the hypothesis(es) the study will test and/or overall objective(s) it will reach.
- **Specific Aims:** Concisely explain the project's specific aims. If this application is part of a larger study, present only tasks that this award would fund.
- **Research Strategy and Feasibility (include only if the application proposes laboratory research studies as a component of the project):** Describe the planned laboratory research studies and how they clearly relate to the clinical trial. Describe the experimental design, methods, analyses, potential problem areas, and alternative methods and approaches. Provide a well-developed, well-integrated, and detailed research plan that supports the translational feasibility and promise of the approach. Where relevant, describe the availability of and access to tissues, data, and/or human subjects necessary for the proposed research. If applicable, provide appropriate letters of support as part of the application's Supporting Documentation (Attachment 2).
- **Clinical Trial:** Provide detailed plans for initiating, conducting, and completing the clinical trial during the period of performance. As appropriate, briefly outline a plan for obtaining regulatory approvals necessary to initiate the clinical trial (e.g., an active Investigational New Drug (IND), Investigational Device Exemption (IDE), or equivalent status). Additional details should be provided in Attachment 9: Regulatory Strategy. Describe the type of clinical trial the team will perform (e.g., prospective, randomized, controlled) and outline the proposed methodology in sufficient detail to show a clear course of action. Describe potential challenges and alternative strategies where appropriate.
  - Identify the intervention the clinical trial will test and describe the projected outcomes.
  - Define the study variables and describe how the study team will measure them. Include a description of appropriate controls and the endpoints the investigators will test.
  - Describe the availability of and access to critical reagents (e.g., therapeutic molecules) necessary for the clinical trial, and provide appropriate letters of support as part of the application's Supporting Documentation (Attachment 2).
  - Identify the study population and specify the number of human subjects the trial will enroll. Indicate the access to the study population, recruitment plans, and inclusion/exclusion criteria. Provide appropriate letters of support demonstrating access to the study population as part of the application's Supporting Documentation (Attachment 2). Describe the strategy for the inclusion of women

and minorities appropriate to the objectives of the study, including a description of the composition of the proposed study population in terms of sex, racial, and ethnic group, and an accompanying rationale for the selection of subjects.

- **Data Collection and Statistical Analysis Plan:** Describe the proposed methods for data collection and analysis in a manner that is consistent with the study objectives. Detail a statistical plan for the resulting outcomes. Include a power analysis to demonstrate the appropriateness of the sample size relative to the objectives of the study. If applicable, explain any anticipated subgroup analyses and justify the appropriateness of the sample size for the subpopulation. If applicable, describe how data will be appropriately reported and documented to support a regulatory filing with the FDA or an equivalent international regulatory agency.
- **Clinical Team:** Describe the composition of the clinical trial team. Provide details on how the team (including investigator(s), study coordinator, statistician) possesses the appropriate experience in conducting clinical trials.
- **Project Coordination and Communication:** Describe plans for communication, decision-making, allocation of resources, coordination of research progress and results, and sharing of data among both PIs and institutions participating in the project.

- **Attachment 2: Supporting Documentation: Combine and upload as a single file named "Support.pdf".**

There are no page limits for these components unless otherwise noted. Include only components described below; inclusion of items not requested or viewed as an extension of the Project Narrative will result in the removal of those items or may result in administrative withdrawal of the application.

- **References Cited:** List the references cited in the Project Narrative using a standard reference format (include URLs, if available).
- **List of Abbreviations, Acronyms and Symbols:** Provide a list of abbreviations, acronyms and symbols.
- **Facilities, Existing Equipment and Other Resources:** Describe the facilities and equipment available for performance of the proposed project; include any additional facilities or equipment proposed for acquisition at no cost to the award. Indicate whether government-furnished facilities or equipment are proposed for use. If so, reference the original or present government award under which the facilities or equipment items are now accountable. There is not a standardized form for this information.
- **Publications and/or Patents:** Include a list of relevant publication URLs and/or patent abstracts. If articles are not publicly available, then copies of up to five published manuscripts may be included in Attachment 2. Extra items will not be reviewed.
- **Letters of Support (one-page limit per letter is recommended):** Provide individual letters signed by collaborating individuals and/or organizational officials demonstrating that the PIs have the support and resources necessary for the proposed work. Letters from the PIs' Department Chair, or appropriate organization official, should also confirm that the PIs meet eligibility criteria. If applicable, provide a letter of support, signed by the lowest-ranking person with approval authority, confirming participation of intramural DOW collaborator(s) and/or access to military

populations, databases or DOW resources. If applicable, provide a letter of support signed by the VA Facility Director(s), or an individual designated by the VA Facility Director(s), confirming access to VA patients, resources and/or VA research space.

- **Sex as a Biological Variable (SABV) Strategy (two-page limit is recommended):** Describe the strategy for how sex will be considered as a biological variable. This strategy should include a brief discussion of what is currently known regarding sex differences in the applicable research area. Clearly articulate how sex as a biological variable will be factored into the data analysis plan and how data will be collected and disaggregated by sex. If needed, provide a strong rationale for proposing a single-sex study, based on justification from scientific literature, preliminary data or other relevant considerations. Refer to the CDMRP Directive on Sex as a Biological Variable in Research for additional information.
- **Inclusion Enrollment Report *(only required if clinical research or a clinical trial is proposed)*:** Provide an anticipated enrollment table(s) for the inclusion of women and minorities using the "Public Health Service (PHS) Inclusion Enrollment Report", a three-page fillable PDF form, that can be downloaded from eBRAP. The enrollment table(s) should be appropriate to the objectives of the study with the proposed enrollment distributed on the basis of sex, race, and ethnicity. Studies utilizing human biospecimens or datasets that cannot be linked to a specific individual, ethnicity, or race (typically classified as exempt from IRB review) are exempt from this requirement.
- **Intellectual and Material Property Plan *(if applicable)*:** Provide a plan for resolving intellectual and material property issues among participating organizations.
- **Commercialization Strategy *(if applicable)*:** Describe the commercialization plan. The plan should include intellectual property, market size, financial analysis, strengths and weaknesses, barriers to the market, competitors, and management team. Discuss the significance of this development effort, when it can be anticipated, and the potential commercial use for the technology being developed.
- **Research Sharing Plan:** Describe the type of data or research resources to be made publicly available as a result of the proposed work. Describe the mechanism (e.g., direct sharing, repository, mixed mode) by which data and resources generated during the period of performance will be shared with the research community and other affected communities, including clinical research participants if applicable. Specifically describe a plan to make animal models, tissue samples, and other resources developed as part of the proposed research project available to the scientific community, if applicable. Include the name of the repository(ies) where scientific data and resources arising from the proposed study will be archived, if applicable. Identify and provide the rationale for any data or resources that will not be shared (e.g., for intellectual property, feasibility, cost, or other considerations). The plan should also protect participant privacy, confidential and proprietary data, and performer/third-party intellectual property. Provide a milestone plan for disseminating data/results including when data and resources will be made available to other users. In cases where the study participant could potentially derive medical or other benefit from the information, explain whether the results of screening and/or study participation will be shared with the participant or their primary care provider, including results from any screening or diagnostic tests performed as part of the study.

Do not submit a copy of the National Institutes of Health (NIH) Data Management and Sharing Plan or duplicate the Data Management Plan which will be requested only after a recommendation for funding is made.

Refer to the CDMRP Directive on Sharing Data and Research Resources for more information about the CDMRP's expectations for making data and research resources publicly available.

- **Attachment 3: Technical Abstract (one-page limit): Upload as "TechAbs.pdf".**

Write the technical abstract using the outline below. Clarity and completeness within the space limits are highly important.

- **Background:** Present the scientific rationale behind the proposed research project. State which FY26 PCARP Focus Area(s) the study will address.
- **Hypothesis/Objective(s):** State the hypothesis the project will test and/or objective(s) it will reach. Provide evidence or rationale supporting the hypothesis(es)/objective(s).
- **Specific Aims:** State the specific aims of the study.
- **Study Design:** Describe the study design, including appropriate controls.
- **Impact:** Summarize how the proposed project is relevant to and will have an impact on the outcomes of individuals with pancreatic cancer, their families/caregivers and/or the understanding of pancreatic cancer.
- **Military Relevance:** Describe how the proposed research is relevant to the health of Service Members, Veterans and/or their Families.

- **Attachment 4: Lay Abstract (one-page limit): Upload as "LayAbs.pdf".**

The lay abstract should address the points outlined below ***in a manner that is readily understood by readers without a background in science or medicine.*** Avoid overuse of scientific jargon, acronyms and abbreviations. ***Do not duplicate the technical abstract.***

- Summarize the objectives and scientific rationale for the proposed research.
- Identify which FY26 PCARP Focus Area(s) the research will address.
- Explain the impact that the proposed research project's results might have on the field of pancreatic cancer research and/or patient care, including the PCARP's vision of diminishing the burden of pancreatic cancer.
- Describe the impact, in the short-term or long-term, on individuals living with pancreatic cancer, their families/caregivers and/or the understanding of pancreatic cancer.
- Explain briefly how the proposed research is relevant to the health of Service Members, Veterans, and/or their Families.

- **Attachment 5: Statement of Work (three-page limit): Upload as "SOW.pdf".** Refer to eBRAP for the Suggested SOW Format.

For guidance on preparing the SOW, refer to either the Example: Assembling a Clinical Research and/or Clinical Trial Statement of Work or Example: Assembling a Generic

Statement of Work, whichever is most appropriate for the proposed effort. Include milestones for data or research resource(s) sharing.

Each PI must submit an identical copy of a jointly created SOW. The specific contributions of the Initiating PI and the Partnering PI should be clearly noted for each task.

- **Attachment 6: Impact Statement (one-page limit): Upload as "Impact.pdf".** Explain in detail the importance of the proposed project, as follows:
  - Describe how the project addresses one or more of the FY26 PCARP Focus Areas as it relates to the PCARP's goal of diminishing the burden of pancreatic cancer among Service Members, Veterans, their Families, and the American public.
  - ***Describe the short-term impact:*** Detail the anticipated outcome(s)/product(s) that will directly result from the proposed research.
  - ***Describe the long-term impact:*** Explain the anticipated long-term gains from the proposed research. Describe how the new understanding could ultimately lead to earlier diagnosis, new therapeutic tools and improved outcomes in patient care and the elimination of pancreatic cancer.
  - If applicable, describe how the anticipated outcomes of the proposed study will make an impact in understanding health differences between sexes.
- **Attachment 7: Partnership Statement (one-page limit): Upload as "Partnership.pdf".** Discuss in detail how the proposed project centers on a unified theme that addresses a central problem or question rather than an additive set of unrelated subprojects. Describe the advantages of addressing the research problem through the combined expertise and synergistic efforts of the PIs. Discuss how the proposed partnership involves a substantial contribution by each partner and the reciprocal flow of ideas and information (e.g., ongoing communication, decision making, allocation of resources, coordination of research progress and results, and data sharing among all participating PIs and institutions). Describe how the partners' combined experience will better address the research question and why the work should be done together than through separate efforts.
- **Attachment 8: Animal Research Plan (three-page limit): Upload as "AnimalResPlan.pdf".** ***(Attachment 8 is only applicable and required for applications proposing animal studies.)***

  If the proposed study involves animals, a summary describing the animal research that will be conducted must be included in the application. Consult the ARRIVE guidelines 2.0 (Animal Research: Reporting *In Vivo* Experiments) to ensure relevant aspects of rigorous animal research are adequately planned for and, ultimately, reported. The Animal Research Plan may not be an exact replica of the protocol(s) submitted to the IACUC. The Animal Research Plan should address the following points to achieve reproducible and rigorous results for each proposed animal study:
  - Briefly describe the research objective(s) of the animal study. Explain how and why the animal species, strain, and model(s) being used can address the scientific objectives and, where appropriate, the study's relevance to human biology.
  - Summarize the procedures to be conducted. Describe how the study will be controlled.

- Describe the randomization and blinding procedures for the study, and any other measures to be taken to minimize the effects of subjective bias during animal treatment and assessment of results. If randomization and/or blinding will not be utilized, provide justification.
- Provide a sample size estimate for each study arm and the method by which it was derived, including power analysis calculations.
- Describe how data will be handled, including rules for stopping data collection, criteria for inclusion and exclusion of data, how outliers will be defined and handled, statistical methods for data analysis, and identification of the primary endpoint(s).

- **Attachment 9: Regulatory Strategy (no page limit): If submitting multiple documents, start each document on a new page. Combine and upload as a single file named "Regulatory.pdf".** ***(Attachment 9 is only applicable and required for applications proposing a clinical trial.)*** Answer the following questions and provide supporting documentation as applicable.
  - State the product/intervention name.

  For products/interventions that do not require regulation by the FDA or an equivalent international regulatory agency:

  - Provide evidence that the clinical trial does not require regulation by the FDA or an equivalent international regulatory agency. Submissions providing "not applicable," "none," or similar responses do not satisfy this request. This attachment requires no additional information.

  For products/interventions that require regulation by the FDA or an equivalent international regulatory agency:

  - Describe the overall regulatory strategy and product development plan the study team will perform during the project's period of performance to support the planned product indication/label. Include, as appropriate, a description of the regulatory application submission strategy.
    - State whether the product is FDA-approved, -licensed, or -cleared, and marketed in the United States. If the product is marketed in the United States, state the product label indication. State whether the proposed research involves a change to the approved label indication.
    - If the product is not currently FDA-approved, -licensed, or -cleared, state the planned indication/use and whether an IND or IDE application was submitted. ***If an IND or IDE is required, the applicant must submit the IND or IDE application to the FDA prior to the FY26 PCARP Translational Research Partnership Award application submission deadline.*** The IND or IDE should be specific for the investigational product (i.e., not a derivative or alternate version of the product) and include the indication that the proposed clinical trial will test. Provide the date of submission, the application number and a copy of the FDA letter acknowledging the submission.
    - Provide a summary of any meetings the research team had with regulatory agencies or consultants regarding the proposed research; include key outcomes, action items and recommendations. If available, provide a copy of the communication from the FDA indicating the IND or IDE application is active/safe to proceed.

- If the applicant will conduct the clinical trial at international sites, provide equivalent information and supporting documentation relevant to the product indication/label and regulatory approval and/or filings in the host country(ies).

- **Attachment 10: Representations *(Grants.gov submissions only)*: Upload as "RequiredReps.pdf".** All extramural applicants must complete and submit the Required Representations document available on eBRAP.

- **Attachment 11: Suggested Intragovernmental/Intramural Budget Form *(if applicable)*: Upload as "IGBudget.pdf".** If an intramural DOW organization will be a collaborator in the performance of the project, complete a separate budget for that organization using the Suggested Intragovernmental/Intramural Budget form available on eBRAP.

(c) Additional Application Materials:

The following are additional forms for application submission. Follow the instructions specific to the submission portal, as found within the GAI.

Grants.gov	eBRAP.org

i. Research & Related Senior/Key Person Profile (Expanded)

- **Biographical Sketch**
- **Current/Pending Support**

  Intragovernmental applicants must include their internally supported research and development programs.

ii. Research & Related Budget

*Initiating and Partnering PIs must have a separate budget and justification specific to their distinct portions of the effort that the applicant organization will submit as separate Grants.gov or eBRAP application packages. The Initiating PI should not include budget information for the Partnering PI, or vice versa, even if they are located within the same organization. Refer to **Section 3.4, Funding Details**, for detailed budget information.*

iii. Project/Performance Site Location(s)

iv. Research & Related Subaward Budget Attachment(s) *(if applicable, Grants.gov submissions only)*

4.3.2. Full Application Components for the Partnering PI

Refer to the equivalent attachment above for details specific to each of the following application components. See Appendix 1 for a checklist of the full application components required for the Partnering PI.

(a) SF424 Research & Related Application for Federal Assistance Form *(Grants.gov Submissions Only)*:

(b) Attachments:

- **Attachment 5: Statement of Work (three-page limit): Upload as "SOW.pdf".** Each PI must submit an identical copy of a jointly created SOW.
- **Attachment 10: Representations *(Grants.gov submissions only)*: Upload as "RequiredReps.pdf".**
- **Attachment 11: Suggested Intragovernmental/Intramural Budget Form: Upload as "IGBudget.pdf".**

(c) Additional Application Materials:

The following are additional application materials for application submission. Follow the instructions specific to the submission portal found within the GAI.

Grants.gov	eBRAP.org

i. Research & Related Senior/Key Person Profile (Expanded)

- **Biographical Sketch**
- **Current/Pending Support**

  Intragovernmental applicants must include their internally supported research and development programs.

ii. Research & Related Budget

*Initiating and Partnering PIs must have a separate budget and justification specific to their distinct portions of the effort that the applicant organization will submit as separate Grants.gov or eBRAP application packages. The Partnering PI should not include budget information for the Initiating PI, or vice versa, even if they are located within the same organization. Refer to **Section 3.4, Funding Details**, for detailed budget information.*

iii. Project/Performance Site Location(s) Form

iv. Research & Related Subaward Budget Attachment(s) Form (if applicable, Grants.gov submissions only)

4.4. Other Application Elements

If recommended for funding, a data management plan compliant with Section 3.c, Enclosure 3, DoD Instructions 3200.12 will be requested.

The government reserves the right to request a revised budget, budget justification and/or additional information for applications recommended for funding.

5. Submission Requirements

5.1. Location of Application Package

Download the application package components for HT942526PCARPTRPA from Grants.gov or eBRAP, depending on which submission portal will be used.

5.2. Unique Entity Identifier and System for Award Management

The applicant organization must be registered as an entity in the System for Award Management (SAM), SAM.gov, and receive confirmation of an "Active" status before submitting an application through Grants.gov. Organizations must include the unique entity identifier (UEI) generated by the SAM in applications to this funding opportunity and maintain an active registration in the SAM at all times during which it has an active Federal award or an application under consideration.

5.3. Submission Instructions

The CDMRP uses two portal systems to accept pre- and full application submissions. The workflow below shows which portal system to use for pre- and full application submissions, respectively.

Application Submission Workflow



5.3.1. Pre-Application Submission

All pre-application components must be submitted by the Initiating PI through eBRAP including the submission of contact information for the Partnering PI.

During the pre-application process, eBRAP assigns each submission a unique log number. This unique log number is required during the full application submission process. The eBRAP log number, application title and all information for the PI, Business Official(s), performing organization, and contracting organization must be consistent throughout the entire pre-application and full application submission process. Inconsistencies may delay application processing and limit or negate the ability to view, modify and verify the application in eBRAP. Contact the eBRAP Help Desk if any changes need to be made.

After the Initiating PI confirms submission of the pre-application, the Partnering PI will be notified of the pre-application submission via an email from eBRAP. ***The Partnering PI must follow the instructions provided in the email to associate the partnering pre-application with their eBRAP account.*** If not previously registered, the Partnering PI must register in eBRAP.

Partnering PIs should not initiate a new pre-application based on the same research project submitted by the Initiating PI. Partnering PIs are urged to associate the partnering pre-application with their eBRAP account as soon as possible. If this is not completed by the full application deadline:

- Any intramural Partnering PI will not be able to submit their full application package components to eBRAP.
- The Partnering PI will not be able to view and modify their full application during the verification period in eBRAP.

When starting the pre-application, PIs should select a Mechanism Option appropriate to their pre-application:

Application Includes:	Select Mechanism Option:
Preclinical or Translational Research	Translational Research Partnership Award (TRPA)
Pilot Clinical Trial	Translational Research Partnership Award With Pilot Clinical Trial Option (TRPA-PCT)

5.3.2. Full Application Submission

Grants.gov Submissions: Full applications from extramural organizations *must* be submitted through the Grants.gov Workspace.

eBRAP Submissions: Only intramural DOW organizations may submit full applications through eBRAP.

5.3.3. Applicant Verification of Full Application Submission in eBRAP

Independent of the submission portal, once the full application is submitted, it is transmitted to and processed in eBRAP; the transmission to eBRAP may take up to 48 hours. At this stage, the PI and organizational representatives will receive an email from eBRAP instructing them to log in to eBRAP to review, modify and verify the full application submission. ***The Project Narrative and Research & Related Budget Form cannot be changed after the application submission deadline.*** Other application components, including subaward budget(s) and subaward budget justification(s), may be changed until the application verification

period ends. The full application cannot be modified once the application verification period ends.

5.4. Submission Dates and Times

The pre-application and full application submission process should be started early to avoid missing deadlines. Regardless of submission portal used, all pre- and full application components must be submitted by the deadlines stipulated in this program announcement. There are no grace periods for deadlines; failure to meet submission deadlines will result in application rejection. ***The DHACA cannot make allowances/exceptions for submission problems encountered by the applicant.***

Submission dates and times are specified in Section 1, Basic Information.

5.5. Intergovernmental Review

Not applicable for this funding opportunity.

6. Application Review Information

6.1. Application Compliance Review

Submitting applications that propose essentially the same research project to different funding opportunities within the same program and fiscal year is prohibited and will result in administrative withdrawal of the duplicative application(s).

While it is allowable to propose similar research projects to different programs within the CDMRP or to other organizations, duplication of funding or accepting funding from more than one source for the same research is prohibited. See the CDMRP's Directive on Research Duplication.

Including classified research data within the application and/or proposing research that may produce classified outcomes or outcomes deemed sensitive to national security concerns, may result in application withdrawal.

Members of the FY26 PCARP Programmatic Panel must not be involved in any pre-application or full application including, but not limited to, concept design, application development, budget preparation and the development of any supporting documentation, including personal letters of support/recommendation for the research and/or PI. Programmatic panel members ***may*** provide letters to confirm PI eligibility and access to laboratory space, equipment and other resources necessary for the project if that is part of their regular roles and responsibilities (e.g., as Department Chair). ***A list of the FY26 PCARP Programmatic Panel members can be found on the CDMRP website.***

Additional restrictions and associated administrative responses are outlined in Section 9.2, Administrative Actions.

6.2. Review Criteria

6.2.1. Pre-Application Screening Criteria

To determine the merits of the pre-application and the relevance to the mission of the Defense Health Program and the PCARP, pre-applications will be screened based on the following criteria:

- **Research Idea:** Whether the proposed research addresses one or more of the FY26 PCARP Focus Areas. How well the scientific rationale, preliminary data, study design and specific aims support the project's objective. If the proposed research includes a clinical trial, whether the pre-application stated the clinical intervention, subject population(s), and phase of the clinical trial.
- **Partnership:** To what extent the proposed study represents a synergistic collaboration that will produce results greater than those of the PIs working independently. To what extent the combined efforts center on a unified objective and demonstrate that the PIs will work together to achieve that objective from different perspectives.
- **Impact:** What potential impact this study will have on the outcomes of individuals with pancreatic cancer, their families/caregivers, and/or the understanding of pancreatic cancer.

6.2.2. Peer Review Criteria

To determine technical merit, all applications will be evaluated individually according to the following **scored criteria**, which are of equal importance:

- **Research Strategy and Feasibility**
    - To what extent the preliminary data, critical review and analysis of the literature, and/or preclinical data support the scientific rationale for the proposed study.
    - How well the application develops the hypothesis or objectives and specific aims.
    - To what extent the experimental design, methods and analyses support achieving reproducible and rigorous results.
    - How well the application acknowledges potential problem areas and addresses alternative methods and approaches.
    - If applicable, how well the applicant designed the animal study (or studies) to achieve the objectives, including, the choice of model(s) and endpoint(s).
    - If applicable, to what extent the application justifies the appropriateness of the human subject population and proposes an appropriate plan for recruitment of subjects or acquisition of samples.
    - Whether there is documented availability of, and access, to tissues, data or human subjects, where relevant.
    - If applicable, whether the strategy for the inclusion of women and minorities and distribution of proposed enrollment are appropriate for the proposed research. Studies utilizing human biospecimens or datasets that cannot be linked to a specific individual, ethnicity, or race (typically classified as exempt from IRB review) are exempt from this requirement.
    - Whether the strategy for considering sex as a biological variable is appropriate to the objectives of the study or whether the justification for a single sex study is sufficiently strong.
    - To what extent the plan for sharing of project data and research resources is appropriate and reasonable and includes dissemination to affected communities, study participants and/or the scientific community. If applicable, whether specific repository(ies) are named where data and research resources arising from the project will be stored.

  In addition, for those applications selecting the Translational Research Partnership Award With Pilot Clinical Trial Option:

    - Whether the application demonstrates that the proposed laboratory research studies are clearly related to the proposed clinical trial.
- **Clinical Trial (Translational Research Partnership Award With Pilot Clinical Trial Option only)**
    - Whether the type of clinical trial (e.g., prospective, randomized, controlled) proposed is appropriate to meet the project's objectives.
    - How well the clinical trial is designed with appropriate study variables, controls, and endpoints the team will test.
    - How well the application demonstrates the availability of, and access to, critical reagents (e.g., therapeutic molecules) necessary for the clinical trial.

- How well the application demonstrates access to the study population and describes appropriate recruitment plans and inclusion/exclusion criteria.
- Whether the strategy for the inclusion of women and minorities and distribution of proposed enrollment is appropriate for the proposed research.
- Whether the strategy for considering sex as a biological variable is appropriate to the objectives of the study, or whether the justification for a single-sex study is sufficiently strong.

- **Regulatory Strategy (Translational Research Partnership Award With Pilot Clinical Trial Option only)**
  - To what extent the regulatory strategy and development plan to support the product indication or product label change, if applicable, are appropriate and well described.
  - Whether the application includes documentation that the clinical trial does not require regulation by the FDA or equivalent international regulatory agency, or whether the application includes documentation demonstrating IND or IDE application (and/or other international equivalent) submission to the respective regulatory agency as appropriate.
- **Statistical Plan**
  - To what extent the statistical plan is appropriate for the proposed experimental and/or clinical methodology.
  - Whether the power analysis for the proposed study demonstrates the appropriateness of the sample size relative to the objectives of the study.
  - If applicable, whether the application adequately explains any anticipated subgroup analyses and justifies the appropriateness of the sample size for the subpopulation.
  - If applicable, whether data will be appropriately reported and documented to support a regulatory filing with the FDA or an equivalent international regulatory agency.
- **Impact**
  - How well the proposed research addresses at least one of the FY26 PCARP Focus Areas.
  - To what extent the proposed study could, whether in the short-term or long-term, make a significant impact on pancreatic cancer research and/or patient care, including the PCARP's vision of diminishing the burden of pancreatic cancer.
  - If applicable, to what extent the anticipated outcomes of the proposed study will make an impact in understanding health differences between sexes.
- **Personnel**
  - To what extent the PIs have assembled an appropriate research team with combined backgrounds and pancreatic cancer-related experience to enable successful conduct of the project.
  - How the partners' combined expertise will better address the research question and why the work should be done together than through separate efforts.
  - To what extent the proposed project is centered on a unified theme that addresses a central problem or question rather than an additive set of unrelated subprojects.

- How well the application addresses processes for ongoing communication, decision-making, allocation of resources, coordination of research progress and results, and data sharing among all participating PIs and institutions.

In addition, the following criteria will also contribute to the overall evaluation of the application, but will not be individually scored and are therefore termed **unscored criteria**:

- **Budget**
  - Whether the budget is appropriate for the proposed research.
- **Environment**
  - To what extent the scientific environment and level of institutional support is appropriate for the proposed research project.
  - How well the research requirements are supported by the availability of and accessibility to facilities and resources.
  - If multi-institutional, to what extent the intellectual and material property plan is appropriate.
- **Application Presentation**
  - To what extent the writing, clarity and presentation of the application components influence the review.

6.2.3. Programmatic Review

To make funding recommendations and select the application(s) that, individually or collectively, will best achieve the program objectives, the following criteria are used by programmatic reviewers:

- Ratings and evaluations of peer reviewers
- Relevance to the priorities of the FY26 PCARP, as evidenced by the following:
  - Adherence to the intent of the funding opportunity
  - Program portfolio balance
  - Programmatic relevance to the FY26 PCARP Focus Areas
  - Partnership and synergy
  - Relative impact

6.3. Application Review and Selection Process

6.3.1. Pre-Application

Following the pre-application screening, Initiating PIs will be notified as to whether they are invited to submit full applications. The estimated date when PIs can expect to receive notification of an invitation to submit a full application is indicated in Section 1, Basic Information about the Funding Opportunity. No feedback (e.g., a critique of the pre-application's strengths and weaknesses) is provided at this stage. Because the invitation to submit a full application is based on the contents of the pre-application, investigators should not change the title or research objectives after the pre-application is submitted.

6.3.2. Full Application

All applications are evaluated by scientists, clinicians and consumers in a two-tier review process. The first tier is **peer review**, the evaluation of applications against established criteria to determine technical merit, where each application is assessed for its own merit, independent of other applications. The second tier is **programmatic review**, a comparison-based process in which applications with high scientific and technical merit are further evaluated for programmatic relevance. Final recommendations for funding are subject to review and approval by a designated official. ***The highest-scoring applications from the first tier of review are not automatically recommended for funding. Funding recommendations depend on various factors as described in Section 6.2.3, Programmatic Review.*** Additional information about the two-tier process used by the CDMRP can be found on the CDMRP website.

Funding of applications received is contingent upon the availability of federal funds for this program, the number of applications received, the quality and merit of the applications as evaluated by peer and programmatic review, and the requirements of the government. Funds to be obligated on any award resulting from this funding opportunity will be available for use for a limited time period based on the fiscal year of the funds.

6.4. Risk, Integrity and Performance Information

Prior to making an assistance agreement award where the federal share is expected to exceed the simplified acquisition threshold, as defined in the Code of Federal Regulations, Title 2, Part 200.1 (2 CFR 200.1), over the period of performance, the federal awarding agency is required to review and consider any information about the applicant that is available in the SAM.

An applicant organization may review the SAM and submit comments on any information currently available about the organization that a federal awarding agency previously entered. The federal awarding agency will consider any comments by the applicant, in addition to other information in the designated integrity and performance system, in making a judgment about the applicant's integrity, business ethics and record of performance under federal awards when determining a recipient's qualification prior to award, according to the qualification standards of the Department of Defense Grant and Agreement Regulations (DoDGARs), Section 22.415.

In accordance with National Security Presidential Memorandum-33 and all associated laws, all fundamental research funded by the DOW must be evaluated for affiliations with foreign entities. All applicant organizations must disclose foreign affiliations of all key personnel named on applications. Failure to disclose foreign affiliations of key personnel shall lead to withdrawal of recommendations to fund applications. Applicant organizations may be presented with an opportunity to mitigate identified risks, particularly those pertaining to influence from foreign entities specified in law. Implementation of mitigation discussions and utilization of the DOD Component Decision Matrix must decrease risk of foreign influence in accordance with the above-mentioned laws and guidance prior to award.

7. Federal Award Notices

For each compliant full application received, the organizational representative(s) and PI will receive email notification when the funding recommendations are posted to eBRAP, typically within 6 weeks after programmatic review. At this time, each PI will receive a peer review summary statement on the strengths and weaknesses of the application and an information paper describing the application receipt and review process for the PCARP award mechanisms. The information papers and a list of organizations and PIs recommended for funding are also posted on the program's page within the CDMRP website. After all awards are made, the CDMRP includes individual award information in a searchable database.

If an application is recommended for funding, after the email notification is posted to eBRAP, a government representative will contact the person authorized to negotiate on behalf of the recipient organization.

Only an appointed DHACA Grants Officer may obligate the government to the expenditure of funds to an extramural organization. No commitment on the part of the government should be inferred from discussions with any other individual. ***The award document signed by the Grants Officer is the official authorizing document (i.e., assistance agreement).***

Intragovernmental obligations of funding will be made according to the terms of a negotiated Inter-Agency Agreement and managed by a CDMRP Science Officer.

Funding obligated to ***intragovernmental and intramural DOW organizations*** will be sent through the Military Interdepartmental Purchase Request (MIPR), Funding Authorization Document (FAD) or Direct Charge Work Breakdown Structure processes. Transfer of funds is contingent upon appropriate safety and administrative approvals. Intragovernmental and intramural DOW investigators and collaborators must coordinate receipt and commitment of funds through their respective Resource Manager/Task Area Manager/Comptroller or equivalent Business Official.

An organization may, at its own risk and without the government's prior approval, incur obligations and expenditures to cover costs up to 90 days before the beginning date of the initial budget period of a new award.

8. Post-Award Requirements

8.1. Administrative and National Policy Requirements

Applicable requirements in the DoDGARs found in 32 CFR, Chapter I, Subchapter C, and 2 CFR, Chapter XI, apply to grants and cooperative agreements resulting from this program announcement.

The GAI contain information regarding administrative requirements and national policy requirements.

Refer to full text of the latest DoD R&D Terms and Conditions and the DHACA Research Terms and Conditions for further information.

If there are delinquencies in technical reporting requirements for any existing DHA or U.S. Army Medical Research and Development Command awards at the applicant organization, DHACA will not issue any new awards to the applicant organization until all delinquent reports have been submitted.

Funded trials are required to post a copy of the informed consent form used to enroll subjects on a publicly available federal website in accordance with federal requirements described in 32 CFR 219. Additionally, the CDMRP requires all funded clinical trials to register and submit study results on ClinicalTrials.gov.

Applications recommended for funding that involve animals, human data, human specimens, human subjects or human cadavers must be reviewed for compliance with federal animal and/or human subjects protection requirements and must be approved by the DHA R&D Office of Research and Regulatory Compliance (ORRC), prior to implementation. This administrative review requirement is in addition to the local Institutional Animal Care and Use Committee (IACUC), IRB or Ethics Committee (EC) review.

8.2. Reporting

For all applications, annual technical progress reports as well as a final technical progress report will be required. For applications proposing a clinical trial, quarterly and annual technical progress reports, as well as a final technical report will be required. Annual and final technical progress reports must be prepared in accordance with the Research Performance Progress Report (RPPR).

PHS Inclusion Enrollment Reporting ***(Required for research proposing clinical research and/or clinical trials)***: Enrollment reporting on the basis of sex, race, and/or ethnicity using the PHS Inclusion Enrollment Report will be required with each annual and final progress report. The PHS Inclusion Enrollment Report is available on eBRAP.

The Award Terms and Conditions will specify whether additional and/or more frequent reporting is required.

Award Expiration Transition Plan: An Award Expiration Transition Plan, using the template available on eBRAP, must be submitted with the final progress report.

Awards resulting from this program announcement may entail additional reporting requirements related to recipient integrity and performance matters. Recipient organizations that have federal contract, grant and cooperative agreement awards with a cumulative total value greater than $10M are required to provide information to the SAM about certain civil, criminal and

administrative proceedings that reached final disposition within the most recent 5-year period and that were connected with their performance of a federal award. These recipients are required to disclose, semiannually, information about criminal, civil and administrative proceedings as specified in the applicable Representations.

8.3. Additional Requirements

Unless otherwise restricted, changes in the Initiating PI or Partnering PI will be allowed on a case-by-case basis, provided the intent of the award mechanism is met.

An organizational transfer of an award supporting the Initiating PI or Partnering PI is discouraged and will be evaluated on a case-by-case basis.

The organizational transfer of an award or partnering awards supporting a clinical trial is strongly discouraged and, in most cases, will not be allowed. Approval of a transfer request will be on a case-by-case basis at the discretion of the Grants Officer.

An organizational transfer of an award will not be allowed in the last year of the original period of performance or any extension thereof.

9. Other Information

9.1. Program Announcement Version

Questions related to this program announcement should refer to the program name, the program announcement name and the program announcement version code CD26_01d.

9.2. Administrative Actions

After receipt of pre-application or full applications, the following administrative actions may occur.

9.2.1. Rejection

The following will result in administrative rejection of the pre-application:

- Preproposal Narrative is missing.

The following will result in administrative rejection of the full application:

- The Project Narrative is missing.
- The Budget is missing.
- Submission of an application for which a letter of invitation was not issued.

9.2.2. Modification

- Pages exceeding the specified limits will be removed prior to reviewing all documents.
- Documents not requested will be removed.

9.2.3. Withdrawal

The following may result in administrative withdrawal of the full application:

- A member of the FY26 PCARP Programmatic Panel is named as being involved in the development or execution of the research proposed or is found to have assisted in the pre-application or application processes.
- The application includes the name(s) of personnel from either of the CDMRP peer or programmatic review companies for which conflicts cannot be adequately mitigated. For FY26, the identities of the peer review contractor and the programmatic review contractor may be found on the CDMRP website.
- Personnel from applicant or collaborating organizations are found to have contacted persons involved in the review or approval process to gain protected evaluation information or to influence the evaluation process.
- The application from an extramural organization, including non-DOW federal agencies, is received through eBRAP.
- The federal government recipient organization (including an intramural DOW organization): (a) cannot accept and execute the entirety of the requested budget in FY26 funds; and/or (b)

cannot coordinate the use of contractual, assistance or other appropriate agreements to provide funds to collaborators.

- The application fails to conform to this program announcement description.
- The application includes URLs, with the exception of links in the References Cited and Publication and/or Patent sections.
- The application includes research data that are classified and/or proposes research that may produce classified outcomes, or outcomes deemed sensitive to national security concerns.
- The same research project is submitted to different funding opportunities within the same program and fiscal year.
- The invited application proposes a different research project than that described in the pre-application.
- Application does not address a FY26 PCARP Focus Area.
- The Initiating PI or Partnering PI does not meet the eligibility criteria.
- If an investigator is named in multiple FY26 PCARP Translational Research Partnership Award applications as Initiating PI or Partnering PI, only the first application received will be accepted; additional applications will be administratively withdrawn.
- The PI(s) did not submit an IND or IDE application (and/or international equivalent) prior to the FY26 PCARP Translational Research Partnership Award full application deadline for a study regulated by a relevant regulatory agency.
- Failure to submit all associated (Initiating and Partnering PI) applications by the deadline.

9.2.4. Withhold

Applications that appear to involve research misconduct will be administratively withheld from further consideration pending organizational investigation. The organization will be required to provide the findings of the investigation to the DHACA Grants Officer for a determination of the final disposition of the application.

Appendix 1. Full Application Submission Checklist

Full Application Components	Uploaded	
	Initiating PI	Partnering PI
SF424 Research & Related Application for Federal Assistance *(Grants.gov submissions only)*	☐	☐
Summary (Tab 1) and Application Contacts (Tab 2) *(eBRAP submissions only)*	☐	☐
Attachments		
Project Narrative – Attachment 1, upload as "ProjectNarrative.pdf"	☐	
Supporting Documentation – Attachment 2, upload as "Support.pdf"	☐	
Technical Abstract – Attachment 3, upload as "TechAbs.pdf"	☐	
Lay Abstract – Attachment 4, upload as "LayAbs.pdf"	☐	
Statement of Work –Attachment 5, upload as "SOW.pdf"	☐	☐
Impact Statement – Attachment 6, upload as "Impact.pdf"	☐	
Partnership Statement – Attachment 7, upload as "Partnership.pdf"	☐	
Animal Research Plan – Attachment 8, upload as "AnimalResPlan.pdf"	☐	
Regulatory Strategy – Attachment 9, upload as "Regulatory.pdf"	☐	
Representations *(Grants.gov submissions only)* – Attachment 10, upload as "RequiredReps.pdf"	☐	☐
Suggested Intragovernmental Budget Form *(if applicable)* – Attachment 11, upload as "IGBudget.pdf"	☐	☐
Additional Application Materials		
Research & Related Senior/Key Person Profile (Expanded)	☐	☐
Attach Biographical Sketch for Senior/Key Persons (Biosketch_LastName.pdf)	☐	☐
Attach Current/Pending Support for Senior/Key Persons (Support_LastName.pdf)	☐	☐
Research & Related Budget	☐	☐
Project/Performance Site Location(s)	☐	☐
Research & Related Subaward Budget Attachment(s) (*if applicable*)	☐	☐

Appendix 2. Acronym List

CDMRP	Congressionally Directed Medical Research Programs
CFR	Code of Federal Regulations
DHA	Defense Health Agency
DHA R&D	Defense Health Agency Research and Development
DHACA	Defense Health Agency Contracting Activity
DOD	U.S. Department of Defense
DoDGARs	Department of Defense Grant and Agreement Regulations
DOW	U.S. Department of War
eBRAP	Electronic Biomedical Research Application Portal
EC	Ethics Committee
ET	Eastern Time
FAD	Funding Authorization Document
FDA	U.S. Food and Drug Administration
FY	Fiscal Year
IACUC	Institutional Animal Care and Use Committee
IDE	Investigational Device Exemption
IND	Investigational New Drug
IRB	Institutional Review Board
M	Million
MIPR	Military Interdepartmental Purchase Request
NIH	National Institutes of Health
ORRC	Office of Research and Regulatory Compliance
PCARP	Pancreatic Cancer Research Program
PDF	Portable Document Format
PHS	Public Health Service
PI	Principal Investigator
R&D	Research and Development
RPPR	Research Performance Progress Report
SABV	Sex as a Biological Variable
SAM	System for Award Management
SF424 R&R	Standard Form 424 (Application for Federal Assistance, Research & Related)
SOW	Statement of Work
TRPA	Translational Research Partnership Award
UEI	Unique Entity Identifier

URL	Uniform Resource Locator
USC	United States Code
VA	U.S. Department of Veterans Affairs